• RAAS-centric frameworks emerged as a unifying paradigm for cardiorenal disease, with ACE inhibitors and angiotensin blockade revealing hemodynamic benefits and renal function modulation across congestive heart failure presentations [2], [4], [5], [8], [10], [12], [15].

• Dialysis-associated cardiovascular pathophysiology and imaging/monitoring patterns reveal accelerated atherosclerosis, dialysis-induced hemodynamic shifts, and cardiac function alterations measured by echocardiography and invasive techniques, underscoring dialysis as a cardiac risk substrate [1], [7], [9], [17], [16], [18].

• Vasodilator and diuretic pharmacotherapy patterns highlight renal hemodynamic responses and potential renal function consequences in heart failure, captured in nitroprusside-based strategies, hydralazine interactions, and diuretic neurohumoral effects [3], [6], [14].

• Imaging and invasive hemodynamic assessments illuminate how renal failure shapes cardiac function, from cardiac output shifts to diastolic function, shaping the understanding of cardiorenal interactions [7], [9], [12], [17].